Minimally Invasive Surgical Instrument Market Hits USD 96.1 Billion By 2033

Trishita Deb
Trishita Deb

Updated · Jun 26, 2024

SHARE: Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
Advertiser Disclosure

At Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.


The Minimally Invasive Surgical Instrument Market is projected to reach USD 86.8 billion by 2032, up from USD 35.1 billion in 2023, growing at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2033. This growth is driven by several factors, including technological advancements in surgical tools, rising prevalence of chronic diseases, and increasing demand for minimally invasive procedures that offer reduced recovery times and lower risk of complications.

Key growth drivers include the continuous innovation in handheld instruments, which are now more ergonomic and precise, improving surgical outcomes. The rise in chronic diseases such as cardiovascular disorders, diabetes, and obesity is also boosting the demand for minimally invasive surgeries. For instance, cardiovascular surgeries, which utilize these advanced instruments, are becoming more common due to the increasing incidence of heart diseases globally.

However, the market faces challenges such as high costs of these advanced instruments and stringent regulatory requirements, which can delay product approvals and market entry. Additionally, a shortage of skilled professionals trained in minimally invasive techniques can hinder market growth.

Recent developments in the market include significant product launches and strategic partnerships. For example, in 2022, Ethicon, part of Johnson & Johnson MedTech, launched the ECHELON 3000 Stapler, a digitally enabled device designed to enhance surgical precision​.

Overall, the Minimally Invasive Surgical Instrument Market is poised for robust growth, driven by technological innovations and increasing adoption of minimally invasive techniques across various medical fields​.

Key Takeaway

  • The incorporation of surgical robotics in minimally invasive surgery has revolutionized the healthcare sector.
  • MISI access organs through keyhole incisions such as arthroscopic, laparoscopic and robotic assisted procedures.
  • By product type analysis, handheld instruments captured a large market share of 23.6%, dominating the MISI market in 2023.
  • By application analysis, orthopaedics segment held a commanding position in the marketplace and holds 24.4% of the market share and promises to show growth during the forecast period.
  • Due to advancements in minimally invasive cardiac surgeries, cardiac segment is anticipated to register robust growth.
  • By end user analysis, hospital segment dominated the MISI market in 2023 and holds 71.8% market share.
  • North America is accounted to hold a measurable market share of 32.49% in recent times.
Minimally Invasive Surgical Instruments Market Size Forecast

Emerging Trends

  1. Technological Advancements: The Minimally Invasive Surgical Instrument Market is witnessing significant growth due to technological advancements in various surgical fields such as cardiac, orthopedic, and neurological procedures. Innovations in device design and functionality are enhancing the precision and safety of surgeries, leading to improved patient outcomes​.
  2. Rise of Surgical Robotics: Surgical robotics are becoming increasingly prevalent in minimally invasive procedures. These advanced systems offer greater accuracy and control, allowing for complex surgeries to be performed with minimal incisions. The integration of robotics is expected to expand further, fueled by their success in enhancing surgical efficiency and safety​.
  3. Expansion in Application Areas: Originally popular in procedures like gallbladder removal and gynecological surgeries, the use of minimally invasive surgical instruments is expanding into areas such as gastroenterology and cosmetic surgery. This trend is driven by the demand for surgeries that reduce patient recovery time and post-operative complications​ .
  4. Increasing Market Penetration in Developing Regions: The Asia-Pacific region, in particular, is experiencing rapid growth in the adoption of minimally invasive surgical instruments. Factors contributing to this include rising healthcare expenditures, growing medical tourism, and increasing awareness about the benefits of minimally invasive procedures​.

Use Cases

  1. Orthopedic Surgeries: Minimally invasive techniques are extensively used in orthopedic surgeries such as hip and knee replacements. These procedures benefit from smaller incisions, which reduce the trauma to the body, lessen the pain, and shorten recovery times compared to traditional surgeries​.
  2. Cardiac Procedures: Minimally invasive instruments play a crucial role in cardiac surgeries, particularly in valve repair and replacement. Devices like transcatheter aortic valve implantation (TAVI) systems allow for heart valve replacements without the need for open-heart surgery, significantly reducing patient risk and improving recovery times.
  3. Gastrointestinal Surgeries: Due to the high prevalence of gastrointestinal disorders like obesity and stomach cancer, there is a growing use of minimally invasive techniques in these areas. These procedures help in reducing the length of hospital stays and improving post-operative outcomes​.
  4. Cosmetic and Bariatric Surgeries: In cosmetic and bariatric surgery, minimally invasive techniques are being adopted to ensure minimal scarring and quicker recovery. The use of these instruments facilitates precise targeting and less invasive tissue manipulation, which is crucial for both aesthetic and medical reasons​.

Recent Developments

  • Medtronic
    • February 2023: Medtronic announced the acquisition of Affera, a company specializing in cardiac mapping and navigation technology. This strategic move enhances Medtronic’s portfolio in the minimally invasive surgical space, particularly for cardiac interventions.
    • April 2023: Medtronic launched the Hugo robotic-assisted surgery system in Europe. This system is designed to deliver precision in various minimally invasive surgeries, marking a significant advancement in Medtronic’s surgical technologies.
    • May 2023: Medtronic secured a contract with the U.S. Veterans Health Administration. This agreement expands the availability of Medtronic’s minimally invasive surgical instruments across a network of federal healthcare facilities, emphasizing their commitment to enhancing surgical outcomes through advanced technologies.
    • June 2023: Medtronic introduced a new line of advanced surgical instruments specifically designed for minimally invasive spine surgery. These instruments are part of their continued innovation in surgical solutions that aim to improve patient recovery times and surgical efficiency.
  • Siemens Healthineer AG
    • May 2024: Siemens Healthineers AG reported their second-quarter financial results for FY2024. The results highlighted strategic advancements and strong performance trends, reaffirming the company’s financial goals for the fiscal years up to 2026. This indicates continued growth and stability in their market position
    • 2022-2025: Siemens Healthineers launched the “New Ambition” phase of its Strategy 2025, beginning in fiscal year 2022. This strategic phase aims to expand their impact across healthcare by focusing on breakthrough innovations in patient twinning, precision therapy, and digital, data, and artificial intelligence (AI) applications. The strategy is set to accelerate revenue growth significantly, with a target of 6 to 8 percent annual growth from 2023 to 2025.
  • HOYA Corporation
    • April 2023: HOYA Corporation made a significant advancement by acquiring a leading developer of innovative surgical devices, expanding its portfolio in minimally invasive surgery. This acquisition is aimed at enhancing HOYA’s capabilities in providing advanced surgical solutions and broadening their market reach, particularly in the Asia-Pacific region​.
    • June 2023: The company launched a new series of endoscopic instruments designed for minimally invasive procedures. These instruments are part of HOYA’s commitment to innovation in the healthcare sector, offering enhanced precision and control, which are critical for complex surgeries. This product launch not only reflects HOYA’s dedication to technological advancement but also strategically positions the company to meet the growing global demand for minimally invasive surgical tools​.
  • Ethicon, Inc. (Johnson & Johnson)
    • May 2024: Ethicon launched the ECHELON LINEAR Cutter, an advanced surgical stapler designed to enhance staple line security in colorectal surgeries. This device integrates Ethicon’s proprietary Gripping Surface Technology (GST) and 3D Stapling Technology, which collectively aim to reduce surgical risks by improving staple line integrity and minimizing tissue slippage.
    • November 2022: Ethicon partnered with CMR Surgical to advance minimally invasive robotic surgery. This collaboration combines Ethicon’s expertise in minimally invasive surgical instruments with CMR Surgical’s modular robotic systems, enhancing commercial reach and surgical precision in selected global markets​.
    • June 2024: Ethicon introduced the ProxiSure Suturing Device, which is tailored for laparoscopic procedures. This device features advanced suturing capabilities with wrist-like maneuverability and a curved needle design, aimed at improving precision and reducing risks in tight surgical spaces​.
  • Depuy Synthes
    • February 2022: DePuy Synthes acquired CrossRoads Extremity Systems, a company specializing in foot and ankle surgical solutions. This acquisition added a broad range of minimally invasive, procedure-specific implants and instruments to DePuy Synthes’ portfolio, enhancing its capabilities in elective foot and ankle procedures which are rapidly growing segments in orthopaedics.
    • June 2024: DePuy Synthes received FDA 510(k) clearance for the VELYS Robotic-Assisted Solution, designed for use in unicompartmental knee arthroplasty. This approval marks a significant advancement in their surgical offerings, emphasizing their commitment to integrating innovative, robotic-assisted technologies that enhance surgical precision and patient outcomes.
    • October 2023: The company also obtained FDA clearance for the TriLEAP Lower Extremity Anatomic Plating System. This development represents their ongoing efforts to expand and improve their solutions in the minimally invasive surgical sector, particularly targeting lower extremity surgical procedures.
  • GE Healthcare
    • August 2023: GE Healthcare launched CardioVisio for Atrial Fibrillation, a digital tool designed to assist clinicians by visualizing longitudinal data relevant for disease progression from multiple sources. This tool is aimed at driving evidence-based clinical decision support directed by updated clinical guidelines​.
    • January 2023: GE Healthcare made significant acquisitions to expand its capabilities in personalized diagnostics and treatments. The company acquired IMACITS and Caption Health early in the year. IMACITS is known for its 3D CT-navigation system that improves procedural accuracy and reduces procedure time for interventional radiologists. Caption Health brings AI-enabled ultrasound software, enhancing GE’s ability to support remote and underserved areas​.
  • B. Braun Melsungen AG
    • March 2022: B. Braun acquired Intermedt Medizin & Technik GmbH, a German company specializing in medical and technical solutions. This acquisition aligns with B. Braun’s strategic focus on expanding its capabilities and product offerings in the medical technology sector​.
    • May 2023: The company extended its collaboration with Pharmacolog i Uppsala AB to include the sales of DrugLog and PrepLog at multiple hospital pharmacies in Portugal. This agreement aims to enhance the safety and efficiency of medication handling and administration in hospitals, further consolidating B. Braun’s presence in European healthcare markets​.
  • Abbott Laboratories
    • September 2023: Abbott completed the acquisition of Bigfoot Biomedical, a company specializing in smart insulin management systems. This strategic move aims to expand Abbott’s presence in diabetes care, complementing its FreeStyle Libre® portfolio of continuous glucose monitoring technology and enhancing its connected solutions for diabetes management​.
    • February 2023: Abbott acquired Cardiovascular Systems Inc., a company known for its innovative solutions in treating vascular and coronary disease. This acquisition was valued at $890 million and serves to broaden Abbott’s portfolio in the cardiovascular market segment, indicating a continued commitment to expanding its influence in minimally invasive medical technologies​.
  • Nuvasive, Inc.
    • August 2023: NuVasive, Inc. was acquired by Globus Medical Inc. This all-stock transaction was valued at approximately $3.1 billion. This merger is a significant strategic move, anticipated to enhance the combined entity’s capabilities in the spine surgery market by leveraging a larger, integrated sales and product development team.
    • January 2024: Post-merger integration processes led NuVasive to lay off 157 employees. This restructuring was part of the company’s efforts to optimize operations and reduce redundancies after its acquisition by Globus Medical​.
  • Zimmer Biomet
    • In January 2023, Zimmer Biomet announced its intention to acquire Embody, a company specializing in collagen-based implants for sports medicine. This acquisition, valued at approximately $275 million, is aimed at enhancing Zimmer Biomet’s offerings in sports medicine, particularly in the area of soft tissue injuries like rotator cuff repairs​.
    • In September 2022, Zimmer Biomet received FDA clearance for its Identity Shoulder System, which is designed for various types of shoulder replacements. This system features convertible technology that aids in anatomic, reverse, and revision shoulder replacements, supporting broader treatment options in orthopedics​.


In conclusion, the global Minimally Invasive Surgical Instrument Market is set to experience robust growth, propelled by technological advancements and increased demand for surgeries that minimize recovery time and complications. Key segments like cardiothoracic and orthopedic surgeries are driving market expansion due to the rising prevalence of related diseases and advancements in surgical techniques. The integration of innovative technologies, such as robotic systems, is enhancing the precision and efficacy of these procedures, making them increasingly preferred by healthcare providers.

Additionally, the Minimally Invasive Surgical Instrument Market is seeing significant activity in terms of strategic collaborations and product innovations aimed at expanding the capabilities of minimally invasive tools. With North America leading the market share and Asia-Pacific emerging as the fastest-growing region, the future looks promising for the adoption of these advanced surgical instruments across the globe​.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Trishita Deb

Trishita Deb

Trishita has more than 8+ years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.

Request a Sample Report
We'll get back to you as quickly as possible